



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/535,585

08/10/2005

Hisac Kume

SPO-121

7558

23557

7590

11/26/2007

SALIWANCHIK LLOYD & SALIWANCHIK

A PROFESSIONAL ASSOCIATION

PO BOX 142950

GAINESVILLE, FL 32614-2950

EXAMINER

SINGH, SATYENDRA K

ART UNIT

PAPER NUMBER

1657

MAIL DATE

DELIVERY MODE

11/26/2007

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	Application No. 10/535,585	Applicant(s) KUME ET AL.	
	Examiner Satyendra K. Singh	Art Unit 1657	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 16 September 2007.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-24 is/are pending in the application.
- 4a) Of the above claim(s) 25-30 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-24 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 10 August 2005 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All    b) ☐ Some \*    c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

### DETAILED ACTION

Applicant's responses (and amendments to claims) filed with the office on 8/27/2007 and 9/16/2007 (a supplemental response) are duly acknowledged.

#### ***Election/Restrictions***

Newly submitted claims 25-30 are directed to inventions that are independent or distinct from the invention originally claimed and elected by applicants for the following reasons:

Claims 25-30 are drawn to inventions **distinct methods of using** distinct nutritional compositions (as recited specifically in newly added claims 25-30) in a patient in need thereof.

- I. Claim 25 is drawn to a **method for suppressing hepatitis in a patient** in need thereof by orally administering a nutritional composition,
- II. Claim 26 is drawn to a **method for improving the pathological condition of inflammatory disease patients** by orally administering a nutritional composition,
- III. Claim 27 is drawn to a **method for suppressing inflammatory cytokine production in a patient** in need thereof, wherein said method comprises orally administering to such a patient, a milk protein hydrolysate,
- IV. Claim 28 is drawn to a **method for suppressing hepatopathy in a patient** in need thereof by orally administering a milk protein hydrolysate,
- V. Claim 29 is drawn to a **method for providing nutrition to a patient with liver cirrhosis** by administering a nutritional composition, and
- VI. Claim 30 is drawn to a **method for providing nutrition to a patient with hepatic failure** by administering a nutritional composition.

The newly added methods (claims 25-30) are patentably distinct from the group of invention originally presented by applicants (see claims 1-24) as they are directed to

Art Unit: 1657

methods involved with distinct diseases, and thus lack the unity of invention. The method of using the composition originally presented by applicants (see instant claim 17) was directed to providing nutrition to a patient with high level of stress, whereas, the newly added claims require patients with distinct disease conditions, which encompass distinct etiologies, treatments, and end points.

The Examiner notes that the instant application is a national stage entry of PCT/JP03/14918 filed under 35 U.S.C. § 371. For purposes of restriction, lack of unity practice has been applied to the pending claims under 35 U.S.C. § 121 and 372. Lack of unity will be reassessed at each stage of prosecution hereafter.

Moreover, PCT Rule 13.2 does not provide for multiple compositions or **multiple methods of use within a single application**. Thus, the first appearing composition is combined with a corresponding first method of use and the additional composition and method claims each constitute a separate group.

The examiner has required restriction between **product and process claims**. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re*

*Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.**

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, newly added claims **25-30 are withdrawn** from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

Claims 1-24 (elected by original presentation, and as currently amended) are examined on their merits, herein, for the applicant's **elected specie** for milk protein hydrolysate, "**whey protein isolate (WPI)**".

#### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

1. Claims 2, 10, and 18 (as currently amended) recite the limitation "**the source of...**" in lines 1-2 of the claims. There is insufficient antecedent basis for this limitation in the broader independent claims 1 and 17 as presented by applicants. Appropriate correction/explanation is required.

#### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

Art Unit: 1657

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

1. Claims 1-24 (as currently amended) are/remain rejected under 35 U.S.C. 103(a) as being unpatentable over Gray et al (US 5,714,472, [A]) in view of Kawai et al (1989; [U2]), Davis et al (US 6,998,259 B1, [B]), and Siegenthaler (1983; [U]), taken with Fritsche et al (US 6,737,076 B2; [C]) and Ohashi et al (US 4,499,076; [A2]).

Claims (as currently amended) are generally directed to a **nutritional composition** (suitable for liver disease patients, and/or patients under high level of invasive stress; see instant claim 17) comprising a milk protein hydrolysate (applicant's elected specie, **whey protein isolate that may be obtained by enzymatic hydrolysis using an endoprotease from *Bacillus licheniformis*, and trypsin, and ultrafiltration, resulting in an HPLC separation profile as shown in figure 1 of the instant specification) in an amount of 0.9 to 3 g per 100 mL of the composition** and a protein **derived from** fermented milk **in an amount of 2.5 to 4.5 g per 100 mL of the composition**, as proteins; a high oleic acid-containing oil and milk lecithin and/or soy lecithin, as lipids; and palatinose (i.e. isomaltulose) as a carbohydrate; and **a method of providing nutrition** to a patient having liver disease and/or a high level of invasive stress comprising administering said nutritional composition to such a patient (see instant claims 1, 9, and 17, as currently amended).

*"[E]ven though **product-by-process** claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process." In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985).*

Gray et al [A] teach an enteral formulation (and a method for providing nutrition using a composition comprising protein, high fat and low carbohydrate; designed for optimized nutrient absorption and wound healing; i.e. for patients under high level of invasive stress) comprising an improved protein source (such as whey protein hydrolysate; see Gray et al, abstract, summary of the invention, column 4; column 5, lines 43-48; examples 2-3, and claims, in particular); a high oleic acid-containing lipid source (as defined in the instant specification on page 14, lines 1-3; such as soy oil; see

Art Unit: 1657

Gray et al, columns 5-6, in particular) including soy oil and lecithin (see Gray et al, column 5, lines 35-37; examples 1-2, in particular); and carbohydrates (such as maltodextrin and corn starch. It is to be noted that Gray et al recognize the need for optimization of an enteral nutritional composition (suitable for patients under high stress) in order to reduce the risk of over hydration, hyperglycemia, and carbohydrate intolerance, and hence the emphasis on appropriate protein content (a reasonable amount such as about 9 g/100 ml of the formulation; see Gray et al, column 7, formula example No. 3, in particular), high lipid diet (see Gray et al, summary of the invention, column 2, lines 43-55, in particular).

However, a nutritional composition comprising a protein derived from **fermented milk** (as recited in instant claims 3-5 and 11-13); wherein the **palatinose** is used as a carbohydrate; and wherein the milk protein hydrolysate may be obtained by an enzymatic (using an endoprotease from *B. licheniformis*, alcalase and trypsin) hydrolysis of a **whey protein isolate (WPI)** (see instant claims 6-8 and 14-16), is not explicitly disclosed by the referenced invention of Gray et al.

Siegenthaler [U] discloses the potential nutritive value of cultured dairy products (i.e. fermented milk products such as **fresh cheese, quark**, and yogurt; see Siegenthaler, summary, page 252-254, in particular) that are especially suitable for use in children (akin to patients with suboptimal digestive system; in place of fluid reconstituted milk preparations that are linked with lactose-intolerance, or handling-related diarrhea among many populations) as it provides many benefits including longer shelf-life of the product at ambient temperatures as well as aid in the digestion of residual lactose after ingestion of such fermented milk compositions.

Davis et al [B] teach a milk protein hydrolysate which is obtained by the enzymatic hydrolysis of **WPI** (whey protein isolate such as BiPRO<sup>TM</sup>; see Davis et al, abstract, summary of the invention, columns 3, 5, 9-10, and claims, in particular) which can be used as a source of antihypertensive peptides (such as having ACE-inhibitory activity) derived from whey proteins (i.e. suitable and beneficial for use in nutritional compositions for patients under high level of invasive stress).

In addition, Kawai et al provide a disclosure for the benefits of **palatinose** (or isomaltulose as a source for low-caloric carbohydrate) for patients with conditions such as diabetes, and explicitly suggest its use in a variety of nutritional supplements as a non-calorigenic sweetener (see Kawai et al, page 338, Introduction, in particular) that causes no known side effects in said patient populations.

Therefore, given the detailed disclosure for all the components of a nutritional composition (and its suitability and use in providing nutrition to patients under high level of stress and trauma) used in the cited prior art references, it would have been obvious to a person of ordinary skill in the nutritional art, at the time this invention was made, to modify (i.e. combination and/or substitution of known components) the composition of Gray et al such that it includes a protein from fermented milk such as from fresh cheese, quark (as taught by Siegenthaler); a milk protein hydrolysate which is obtained by enzymatic hydrolysis of a WPI (as explicitly taught by the referenced invention of Davis et al); and a non-calorigenic carbohydrate such as palatinose (as explicitly suggested by Kawai et al).

Art Unit: 1657

One of ordinary skill in the art would have been motivated to modify the composition of Gray et al with a reasonable expectation of success using the combined teachings and suggestions of Siegenthaler, Kawai et al, and Davis et al because they explicitly provide suggestions (such as ease of digestibility, anti-hypertensive properties of peptides derived from WPI, and non-calorigenic substitute for use as a carbohydrate source) and method of preparation of such composition (see discussion above) that are suitable for use with patients having compromised digestive system, and/or under high invasive stress conditions, as intended by instant invention.

The claimed limitation of specific ranges of protein contents (as recited for milk protein hydrolysate and for protein derived from fermented milk; see instant claims 1, 9 and 17, as currently amended) would have been obvious to an artisan of ordinary skill in the nutritional formulation art, as evidenced by the fact that Gray et al disclose and exemplify a similar protein amounts of about 9 g per 100 ml in their ready-to-use enteral product formulation (see also discussion above). Moreover, **low-protein dietary formulations** have been suggested in past to be used for patients with chronic liver diseases as one of the basic therapeutic tools as disclosed explicitly by Ohashi et al (see column 1, 2<sup>nd</sup> paragraph, in particular) in order to avoid side effects such as diarrhea, or even renal insufficiency, etc., and therefore, such optimization in the amounts of proteins (i.e. from various protein sources) used in the nutritional formulations would have been routine for an artisan of ordinary skill in the art at the time this invention was made.

Similarly, the claimed limitations of instant claims 7-8 and 15-16 (which is a permeate obtained by further treatment with an ultrafiltration membrane having a molecular weight of 10,000 Daltons, and wherein the chromatogram from reversed phase HPLC separation is shown in Fig. 1.) would have been a matter of routine optimization to a person of ordinary skill in the art at the time this invention was made, as evidenced by the disclosure of Davis et al (and as supported further by the invention of Fritsche et al [C] that discloses the use of alcalase (i.e. an endoprotease from *B. licheniformis*), trypsin, and other endoproteases, or combinations thereof to hydrolyse protein sources such as WPI; see column 4, lines 44-65; columns 5-6; example 2-3; and use of ultrafiltration and HPLC separation procedures to obtain the peptides derived from the hydrolysate of WPI) for the preparation of enzymatic hydrolysate of WPI and its use as a component having major nutritional as well as health benefits.

Thus, the invention as a whole would have been *prima facie* obvious to a person of ordinary skill in the nutritional art at the time the claimed invention was made.

*As per MPEP 2144.06, In order to rely on equivalence as a rationale supporting an obviousness rejection, the equivalency must be recognized in the prior art, and cannot be based on applicant's disclosure or the mere fact that the components at issue are functional or mechanical equivalents. In re Ruff, 256 F.2d 590, 118 USPQ 340 (CCPA 1958).*

*As per MPEP 2144.06, "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art." In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980).*



*As per MPEP 2144.05 [R3], II. OPTIMIZATION OF RANGES - A. Optimization Within Prior Art Conditions or Through Routine Experimentation: Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955).*

### **Response to Applicant's Arguments**

Applicant's arguments filed with the office on 8/27/2007 (along with a supplemental response submitted on 9/16/2007), as they pertain to the prior art rejection of record over pending claims 1-24, have been fully considered but they are not persuasive for the following reasons of record.

Applicants argue (see response, page 8, in particular) that "the preferable amount of proteins" in the product disclosed by Gray et al is 9.4 g/100 mL, and "the preferable amount of protein hydrolysate disclosed by Gray et al is 7.52 to 7.99 g/100 mL, which greatly exceeds the content of milk protein hydrolysate in the nutritional composition of the present invention". This is not found to be persuasive because the instant claim is directed to 7.5 g/100 mL total protein derived from milk protein hydrolysate plus protein derived from fermented milk. Thus, the differences in the amounts of total protein in the compositions do not appear to be significantly different. Optimizations in the amount of protein contents would have been obvious to an artisan of ordinary skill in the nutritional art given the combined teachings and suggestions of the cited prior art references (Gray et al in view of Kawai et al, Davis et al and Siegenthaler (1983; [U]), taken with Fritsche et al and Ohashi et al) as relied upon in the obviousness rejection of record discussed above.

Applicant's arguments regarding the lack of suitability of the composition disclosed in the cited prior art (see page 9, in particular) for patients with high level of invasive stress as it would contain "whole proteins" from fermented milk, is not found to be persuasive because 1) Siegenthaler clearly suggests the use of fermented milk products such as yogurt, quark for use in children that have compromised digestion profile (see discussion above) in order to provide nutrition in the form of an easily digestible nutrient source, and 2) the fermented milk not only has "whole proteins", as asserted by applicants, but it also has significant amounts of peptides, some of which are known to have several beneficial and nutritional properties. Moreover, the extent of digestion, or the digestion profile of proteins derived from fermented milk, as claimed, is unclear.

Applicant's arguments regarding the intended use of the nutritional composition (see pages 10 and 11, in particular) as disclosed in the cited prior art references is not found to be persuasive because all the components of the composition as claimed are disclosed and/or suggested by the prior art references cited for nutritional purposes, and it would have been obvious to an artisan of ordinary skill in the art to optimize their specific amounts depending on the suitability of the purpose in hand. The argument that one of ordinary skill in the art would not have had a motivation to use palatinose as a carbohydrate source in a reduced carbohydrate composition of Gray et al, is not found to be persuasive because, that is precisely the reason why an artisan of ordinary skill would like to substitute the use of other regular sugars or carbohydrates in the nutritional compositions that are intended to be used by patients with compromised

digestive system, or for that matter patients that are under high levels of stress. In the absence of any evidentiary data to support such arguments, the composition as disclosed in the art cited in the rejection is deemed to meet all the limitations of the composition as claimed in the instant invention.

The presentation of "surprisingly advantageous effect achieved by the nutritional composition of the present invention" (see response, page 11, first paragraph, in particular), as asserted by applicants (in the form of newly added claims 25-30) is interesting, and is duly noted. However, the scope of the invention as claimed (see instant claim 1, 9 and 17, in particular) is not commensurate with the surprisingly advantageous effects touted by applicants, or as presented in the original disclosure using, for example, a hepatopathy model in experimental animals such as rats (see instant disclosure, Figure 2, in particular). The correlation between the cited results in the figure and the invention as claimed is uncertain.

The obviousness rejection of record over cited prior art references is therefore deemed proper and is maintained.

### ***Double Patenting***

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

Art Unit: 1657

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-24 (as currently amended) are/remain provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 2, 37 and 38 of copending Application No. 10/487,237 (from the same inventive entity and same assignee, Meiji Dairies Corp. Tokyo, JP). Although the conflicting claims are not identical, they are not patentably distinct from each other because claims 1, 2, 37 and 38 in the copending application 10/487,237 are also directed to a composition (and methods of using the said composition) comprising protein (such as milk proteins), a lipid (such as high oleic acid containing oils, and milk phospholipids), and a carbohydrate (such as palatinose and/or trehalulose). Although, the composition as recited in the copending application 10/487,237 requires certain range of energy percentage supplied from the components (such as proteins, lipids, and carbohydrate), such distribution of the components based on the caloric input would have been a matter of routine optimization to a person of ordinary skill when using the said composition for a particular patient or subject population depending on the nutritional/caloric requirements. The two sets of composition claims are largely coextensive, and thus raise an issue of obviousness-type double patenting.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

### ***Response to Applicant's Arguments***

Since, applicants have deferred a substantial response against the ODP rejection of record (see response, page 11) until an allowable subject matter is established in the instant application, the rejection of record as set forth above is still deemed proper, and is therefore, maintained.

### ***Pertinent prior art not relied upon in the Rejections***

The following prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

1. FUCHS et al. (US 6,592,863 B2; issued on July 15, 2003), Method to provide nutritional composition; abstract, summary, examples and claims.
2. BUCKE et al. (US 4,587,119; issued on May 6, 1986), Method of reducing dental plaque formation with products for human or animal consumption using isomaltulose sucrose substitute; abstract, columns 5-6.

Art Unit: 1657

3. OJIMA et al. (US 7,029,717 B1; issued on April 18, 2006), Sucralose-containing composition and edible products containing the composition, abstract, columns 7-8, in particular.
4. FORSE et al. (US 5,821,217; issued on October 13, 1998) Enteral formulation: low in fat and containing protein hydrolysates (see entire document).

### **Conclusion**

**NO claims are allowed.**

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Satyendra K. Singh whose telephone number is 571-272-8790. The examiner can normally be reached on 9-5MF.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon P. Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Satyendra K. Singh  
Patent Examiner  
Art Unit 1657

*Irene Marx*  
**IRENE MARX**  
**PRIMARY EXAMINER**